Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered ABF- 101

NCT07330674 is registered in ClinicalTrials.gov with Aptabio Therapeutics, Inc. as lead sponsor.

NCT NCT07330674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07330674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered ABF- 101
Lead sponsor
Aptabio Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 28, 2026
Completion date
December 31, 2027
Enrollment
68 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age related macular degeneration (armd), amd - age-related macular degeneration